Table 1.
Histopathological characteristics of patient cohort used in the IHC analysis.
| Parameter | Pure DCIS | DCIS + IDC | IDC |
|---|---|---|---|
| (n = 12) (%) | (n = 44) (%) | (n = 100) (%) | |
| Age (yrs) | |||
| Range | 36–81 | 41–91 | 29–95 |
| Mean | 53 (13.3) | 58.16 (12.11) | 50.65 (12.3) |
| Tumor grade | |||
| Grade I | 8.3% | 0% | 6% |
| Grade II | 66.7% | 45.7% | 72.7% |
| Grade III | 25% | 54.3% | 21.3% |
| ER status | |||
| Positive | 9% | 73.8% | 68% |
| Negative | 91% | 26.2% | 32% |
| PR status | |||
| Positive | 18.2% | 61.7% | 57% |
| Negative | 81.8% | 39.3% | 43% |
| Her2 status | |||
| Positive | 36.4% | 23.23% | 40% |
| Negative | 63.6% | 76.76% | 60% |
| Ki67 | |||
| Low | 63.5% | 62.4% | 64% |
| High | 36.5% | 38.6% | 36% |
The cohort included patients with DCIS, IDC, and with different molecular subtypes.